Open AccessTime to embrace access programmes for medicines: lessons from the South African flucytosine access programme
Author(s) -
Amir Shroufi,
Nelesh P. Govender,
Graeme Meintjes,
John Black,
Jeremy Nel,
MahomedYunus S. Moosa,
Colin Menezes,
Halima Dawood,
Douglas Wilson,
Laura Triviño Durán,
Olawale Ajose,
Richard A. Murphy,
Thomas S. Harrison,
Angela Loyse,
Carol Ruffell,
Gilles Van Cutsem
Publication year - 2020
Publication title -
international journal of infectious diseases
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.278
H-Index - 89
eISSN - 1878-3511
pISSN - 1201-9712
DOI - 10.1016/j.ijid.2020.02.057
Subject(s) - flucytosine , medicine , business , amphotericin b , antifungal , dermatology
Cryptococcal meningitis (CM) is estimated to cause 181 000 deaths annually, with the majority occurring in Sub-Saharan Africa. Flucytosine is recommended by the World Health Organization as part of the treatment for CM. Widespread use of flucytosine could reduce mortality in hospital by as much as 40% compared to the standard of care, yet due to market failure, quality-assured flucytosine remains unregistered and largely inaccessible throughout Africa.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom